University of Utah
Salt Lake City, Utah, 84108, United States
NCT Number: NCT06087991
This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah.
Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Salt Lake City, Utah, 84108, United States
Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose.
The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah.
This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For qualitative interviews with providers, administrators, stakeholders:
For the quantitative surveys:
Exclusion criteria
For qualitative interviews with providers, administrators, stakeholders:
For the quantitative surveys:
ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
Time frame: 24 months
Will be the aggregate number of individuals who received ED-initiated buprenorphine.
Time frame: 24 months.
Qualitative interviews including clinicians, hospital staff, and community members associated with Castleview Hospital will be the investigators using the Consolidated Framework for Implementation Research (CFIR).
Time frame: enrollment and 6 months post enrollment
Patient satisfaction will be assessed using the Patient Satisfaction Questionnaire Short Form (PSQ-18)
Time frame: enrollment and 6 months post enrollment
Using the Government Performance and Results Act (GPRA) Outcome questions on substance use within the past 30 days, other substance use disorder diagnoses and treatment in the past 30 days, and mental health diagnoses.
Time frame: enrollment and 6 months post enrollment
Social connectedness will be measured using the GPRA questions on mutual support group attendance in the last 30 days and relationship satisfaction and support.
Time frame: enrollment and 6 months post enrollment
Living conditions will be measured using the GPRA questions on residence within the past 30 days.
Time frame: enrollment and 6 months post enrollment
Mental and physical health problems and treatment/recovery will be measured using the GPRA questions on mental health symptoms and medical care received in the past 30 days and insurance status.
Time frame: enrollment and 6 months post enrollment
Legal status will be measured using the GPRA questions on incarceration in the past 30 days, charges, trial, sentencing, parole, probation, and drug court status.
Time frame: enrollment and 6 months post enrollment
Discharge status will be measured using the GRPA questions on substance use diagnosis and treatment in the past 30 days.
Time frame: enrollment and 6 months post enrollment
Follow-up status will be measured using the GPRA questions on contact and follow-up status.
Time frame: enrollment and 6 months post enrollment
Education, employment, and income will be measured using the GPRA questions on education level, employment status, living expenses and income status.
Jerry Cochran
Other
Acronym: BINDeR-TX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04839978
Chemically-Induced Disorders, Mental Disorders
Tahlequah, Oklahoma, United States
View Trial DetailsNCT04758637
Chemically-Induced Disorders, Mental Disorders
Chicago, Illinois, United States
View Trial DetailsNCT04018664
Chemically-Induced Disorders, Mental Disorders
Toronto, Ontario, Canada
View Trial DetailsNCT04601480
Chemically-Induced Disorders, Mental Disorders
Minneapolis, Minnesota, United States
View Trial Details